MedPath

Primaquine

Generic Name
Primaquine
Drug Type
Small Molecule
Chemical Formula
C15H21N3O
CAS Number
90-34-6
Unique Ingredient Identifier
MVR3634GX1
Background

An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)

Indication

For the treatment of malaria.

Associated Conditions
Malaria, Malaria caused by Plasmodium ovale, Malaria caused by plasmodium vivax, Pneumocystis Jirovecii Pneumonia
Clinical Trials
Related News

Phase 2 Efficacy Study of Primaquine and Methylene Blue

Phase 2
Completed
Conditions
Malaria
Interventions
Drug: Sulphadoxine-pyrimethamine
First Posted Date
2016-07-13
Last Posted Date
2017-01-11
Lead Sponsor
University of California, San Francisco
Target Recruit Count
80
Registration Number
NCT02831023
Locations
🇲🇱

Malaria Research and Training Centre, Bamako, Mali

Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria

Phase 3
Completed
Conditions
Malaria, Vivax
Interventions
Drug: Dihydroartemisinin-piperaquine (DHA-PQP)
Drug: ACT plus PQ (Rescue medication)
Drug: PQ (End of study treatment)
First Posted Date
2016-06-16
Last Posted Date
2020-07-24
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
150
Registration Number
NCT02802501
Locations
🇮🇩

GSK Investigational Site, Jakarta, Indonesia

A Trial on Supervised Primaquine Use in Ethiopia

First Posted Date
2016-06-08
Last Posted Date
2017-02-08
Lead Sponsor
Menzies School of Health Research
Registration Number
NCT02793388

Pharmacokinetic Study of Primaquine in Healthy Obese Thai Adult Subjects

Phase 1
Completed
Conditions
Obese
Interventions
First Posted Date
2016-06-03
Last Posted Date
2016-06-03
Lead Sponsor
University of Oxford
Target Recruit Count
10
Registration Number
NCT02789566
Locations
🇹🇭

Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Methylene Blue Against Vivax Malaria in Ethiopia

Phase 2
Withdrawn
Conditions
Vivax Malaria
Interventions
Drug: Artemeter-Lumefantrine (combination therapy)
Drug: Artemeter-Lumefantrine and MB (combination therapy)
First Posted Date
2016-03-02
Last Posted Date
2020-03-25
Lead Sponsor
Heidelberg University
Registration Number
NCT02696928

Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects

First Posted Date
2016-03-02
Last Posted Date
2019-06-28
Lead Sponsor
University of Oxford
Target Recruit Count
17
Registration Number
NCT02696954
Locations
🇹🇭

Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection

Phase 2
Completed
Conditions
Malaria, Vivax
Interventions
First Posted Date
2016-02-25
Last Posted Date
2016-02-25
Lead Sponsor
Oswaldo Cruz Foundation
Target Recruit Count
204
Registration Number
NCT02691910
Locations
🇧🇷

Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

🇧🇷

Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil

Malaria Elimination Pilot Study in Military Forces in Cambodia

Phase 4
Conditions
Malaria
Parasitic Diseases
Interventions
Drug: DHA-PIP
First Posted Date
2016-01-13
Last Posted Date
2021-03-02
Lead Sponsor
Armed Forces Research Institute of Medical Sciences, Thailand
Target Recruit Count
1050
Registration Number
NCT02653898
Locations
🇰🇭

RCAF treatment facilities, Anlong Veng, Oddar Meancheay, Cambodia

Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali

Phase 1
Completed
Conditions
Malaria
Interventions
First Posted Date
2015-08-31
Last Posted Date
2017-02-06
Lead Sponsor
University of California, San Francisco
Target Recruit Count
28
Registration Number
NCT02535767
Locations
🇲🇱

Malaria Research and Training Centre, Bamako, Mali

Safety and Tolerability of Low Dose Primaquine

Phase 4
Completed
Conditions
Malaria, Falciparum
G6PD Deficiency
Interventions
First Posted Date
2015-05-06
Last Posted Date
2016-08-23
Lead Sponsor
Malaria Consortium
Target Recruit Count
109
Registration Number
NCT02434952
Locations
🇰🇭

Ratanakiri Provincial Hospital, Ratanakiri, Cambodia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy